{"id":728743,"date":"2023-02-06T04:03:09","date_gmt":"2023-02-06T09:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/"},"modified":"2023-02-06T04:03:09","modified_gmt":"2023-02-06T09:03:09","slug":"alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/","title":{"rendered":"Alvotech Enters Into Commercialization Agreement  With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair<sup>\u00ae<\/sup> (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>REYKJAVIK, Iceland, Feb.  06, 2023  (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair<sup>\u00ae<\/sup> (omalizumab). The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand.<\/p>\n<p>\u201cWe look forward to working with Advanz Pharma on the commercialization of this important therapy in respiratory disease,\u201d said Anil Okay, Chief Commercial Officer of Alvotech. \u201cThis agreement highlights our joint commitment to provide better patient access to more affordable biologics around the world.\u201d<\/p>\n<p>According to the agreement, Alvotech will be responsible for development and manufacture, while Advanz Pharma will handle registration and commercialization. The estimated market size of the reference product for the region included under this agreement is over US$ 1 bn, according to market data from IQVIA.<\/p>\n<p>\n        <strong>About AVT23 <\/strong><br \/>\n        <br \/>In <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lKZS9qVVa5LtAUx4KMyRSEY_bL4N7xagb0VYydxEdyBf0_N477D25hcChJkhicnluXXf_Nx_LUODEA4ps0mdestkEp6FXKxv4r70JBFGsZwnSyVOly1UeR7ZbaglUfUJuADifWgJEyBbP_8V6xcG7cQBFEYQ2vdaeC5YsaxvXqRG42S1MFFH9-6jGTph8ycFYR8HFpiIpIZs5n2mFx_vtw==\" rel=\"nofollow noopener\" target=\"_blank\">February 2022<\/a>, Alvotech announced an exclusive global licensing agreement with BiosanaPharma for the co-development of AVT23. Omalizumab is an antibody that targets free IgE and is used to treat patients with allergic asthma, chronic spontaneous urticaria (CSU) and nasal polyps. AVT23 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.<\/p>\n<p>\n        <strong>About Alvotech<\/strong><br \/>\n        <br \/>Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech\u2019s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech\u2019s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla\/Cipla Gulf\/Cipla Med Pro (Australia, New Zealand, South Africa\/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility\u00a0for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kGTh9_d5G9Lu4c537DNY6OZomtxygLxqzlQt5Ki1lJ5w-HdaHR6k7q8yyJJr4lMrnbUBjgyH1iXbiyY_Dpf67Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.alvotech.com<\/u><\/a>. None of the information on the Alvotech website shall be deemed part of this press release.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this communication may be considered \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech\u2019s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the success of its commercial partnerships, including its partnership with Advanz Pharma, potential milestone and royalty payments, the potential approval and commercial launch of its product candidates, the timing of regulatory approvals and market launches, and the estimated size of the total addressable market of Alvotech\u2019s pipeline products, and the commercial success of AVT23, Alvotech\u2019s ability to improve global access to affordable biologics, and the effect of biosimilars on inflationary pressures for healthcare systems. In some cases, you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cpredict\u201d, \u201cpotential\u201d, \u201caim\u201d or \u201ccontinue\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech\u2019s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) changes in applicable laws or regulations; (3) the possibility that Alvotech may be adversely affected by other economic, business, and\/or competitive factors; (4) Alvotech\u2019s estimates of expenses and profitability; (5) Alvotech\u2019s ability to develop, manufacture and commercialize the products and product candidates in its pipeline, including AVT23; (6) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (7) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (8) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (9) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (10) the ability of Alvotech\u2019s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (11) Alvotech\u2019s ability to obtain and maintain regulatory approval or authorizations of its products, including AVT23, including the timing or likelihood of expansion into additional markets or geographies; (12) the success of Alvotech\u2019s current and future collaborations, joint ventures, partnerships or licensing arrangements, including the partnership with Advanz Pharma; (13) Alvotech\u2019s ability, and that of its commercial partners, to execute their commercialization strategy for approved products, including AVT23; (14) Alvotech\u2019s ability to manufacture sufficient commercial supply of its approved products, including AVT23; (15) the outcome of ongoing and future litigation regarding Alvotech\u2019s products and product candidates; (16) the potential impact of the ongoing COVID-19 pandemic on the FDA\u2019s review timelines, including its ability to complete timely inspection of manufacturing sites; and (17) other risks and uncertainties set forth in the sections entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.<\/p>\n<p>\n        <strong>CONTACTS<\/strong><br \/>\n        <br \/>\n        <strong>Alvotech Investor Relations and Global Communications<\/strong><br \/>\n        <br \/>Benedikt Stefansson<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SiFBOVwBbA5lZ0NrewEMFd2KAJMtWYUTqJarQuyxZ9z128eQ0N19aZRBAaoqaoUzWxx0kaQgZMtuCRs07loAF3Fdmh0_HoYELnYokurZRUm8CwhEBpEPnJuiYhZfy1v_\" rel=\"nofollow noopener\" target=\"_blank\"><u>alvotech.ir[at]alvotech.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Mzk1MTVhOGYtYTY5NC00M2I0LWIyYmUtNDRiNWJlMGVjN2Q5LTEyNDUzODY=\/tiny\/Alvotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab). The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand. \u201cWe look forward to working with Advanz Pharma on the commercialization of this important therapy in respiratory disease,\u201d said Anil Okay, Chief Commercial Officer of Alvotech. \u201cThis agreement highlights our joint commitment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alvotech Enters Into Commercialization Agreement  With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728743","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab). The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand. \u201cWe look forward to working with Advanz Pharma on the commercialization of this important therapy in respiratory disease,\u201d said Anil Okay, Chief Commercial Officer of Alvotech. \u201cThis agreement highlights our joint commitment &hellip; Continue reading &quot;Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T09:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)\",\"datePublished\":\"2023-02-06T09:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/\"},\"wordCount\":1367,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/\",\"name\":\"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\",\"datePublished\":\"2023-02-06T09:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/","og_locale":"en_US","og_type":"article","og_title":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk","og_description":"Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair\u00ae (omalizumab). The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand. \u201cWe look forward to working with Advanz Pharma on the commercialization of this important therapy in respiratory disease,\u201d said Anil Okay, Chief Commercial Officer of Alvotech. \u201cThis agreement highlights our joint commitment &hellip; Continue reading \"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-06T09:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)","datePublished":"2023-02-06T09:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/"},"wordCount":1367,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/","name":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==","datePublished":"2023-02-06T09:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDkxMyM0MDE0Nzg4MDUjMjIzMzgzMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728743"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728743\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}